Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspartate transcarbamoyl transferase (ATCase) is a key enzyme in the de novo biosynthesis of pyrimidine nucleotides. It catalyzes the committed step in this pathway: the condensation of carbamoyl phosphate and L-aspartate to form N-carbamoyl-L-aspartate and inorganic phosphate. This reaction is essential for producing pyrimidine rings, which are building blocks for DNA and RNA. ATCase activity is tightly controlled by feedback inhibition (CTP) and activation (ATP), ensuring balanced production of purines and pyrimidines within cells. The holoenzyme consists of six catalytic and six regulatory subunits, displaying classic allostery with two main conformational states (T and R). While most detailed studies focus on *E. coli*, similar structures have been solved from other organisms.
Inhibition of pyrimidine biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aspartate transcarbamoyl transferase (ATCase).